Catherine Priest News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy

Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesDavid blumElizabeth wolffeSylvia wheelerCoryr nicholasOregon health science universityCalifornia institute for regenerative medicineCenters for diseaseTherapeutics presents one year dataFirst patient treatedOngoing phaseDrug resistant focalAnnual meetingInternational societyStem cell researchMedical university

Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy

Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesDavid blumCoryr nicholasElizabeth wolffeSylvia wheelerOregon health science universityCenters for diseaseCalifornia institute for regenerative medicineAnnual meetingInternational societyStem cell researchNeurona therapeuticsMedical universityOregon healthScience universityCatherine priest

Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy

United statesElizabeth wolffeCoryr nicholasDavid blumSylvia wheelerCalifornia institute for regenerative medicineOregon health science universityCenters for diseaseAnnual meetingInternational societyStem cell researchNeurona therapeuticsMedical universityOregon healthScience universityCatherine priest

Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy

Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCoryr nicholasElizabeth wolffeCalifornia institute for regenerative medicineSafety monitoring boardEmerging therapiesCatherine priestCellular technologiesData safety monitoring boardCalifornia instituteRegenerative medicineClinical trialMesial temporal lobe epilepsyMedia contacts

Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society

Data from IND-enabling studies show accurate delivery, targeted biodistribution, favorable safety profile, durable suppression of seizures and reduction in disease pathology A first-in-human.

United statesSylvia wheelerElizabeth wolffeDavid blumCalifornia institute for regenerative medicineDrug administrationMeeting of the american epilepsy societyCatherine priestAnnual meetingAmerican epilepsy societyCalifornia instituteRegenerative medicineMedia contacts